Drugs / Hexylaminolaevulinate
last change Nov 2015 re-read 2 minutes ago

Hexylaminolaevulinate

also known as Hexyl-5-aminolaevulinate
Developed for
actinic keratosis
Investigated by
Helsinki University Central Hospital · Joint Authority for Päijät-Häme Social and Health Care

Trials 1 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02149342 May 2014 → Sep 2015 actinic keratosis Joint Authority for Päijät-Häme Social and Health Care Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Hexylaminolaevulinate ClinicalTrials.gov intervention name — accepted as the source's own label NCT02149342
Known as Hexyl-5-aminolaevulinate Hexyl-5-aminolaevulinate 0·2% vs. methyl-5-aminolaevulinate 16% daylight photodynamic therapy for treatment of actinic keratoses: results of a randomized double-blinded pilot trial.” PMID 26011755 Nov 2015
Route Topical Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate” NCT02149342